SOLV · 8-K · 20260805PR000043

Acquisition / Partnership / Divestiture

Solventum Corp · 2026-08-05 · Importance 64 · Surprise 42 · No source text

Solventum intends to pursue a separation of its Health Information Systems business, which generated $1.4 billion in net sales for the twelve months ended December 31, 2025. The company is evaluating alternatives including establishing Health Information Systems as an independent company, combining it with a scaled industry player, or pursuing another transaction structure. Solventum is targeting completion within 12 to 18 months, although no ultimate structure or timing decision has been made and any transaction would require Board approval, regulatory requirements and other customary conditions. Solventum expects the separation to sharpen its focus on MedSurg and Dental Solutions while giving Health Information Systems greater strategic focus, operational agility and capital allocation flexibility to pursue growth, including international expansion, autonomous coding adoption, partnerships and acquisitions.

Key facts

• The company is targeting completion of the separation within 12 to 18 months. source
• Solventum announced its intention to pursue a separation of its Health Information Systems business as part of the company's ongoing portfolio optimization strategy. source
• As a separate company, Health Information Systems intends to pursue partnerships and acquisitions that reinforce its position in healthcare revenue cycle technology. source
• Solventum is evaluating separation alternatives including an independent company, combined with a scaled player in the space or other transaction. source
• Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC are acting as financial advisors to Solventum and Cleary Gottlieb Steen & Hamilton LLP is acting as legal counsel. source
• As a separate company, Solventum intends Health Information Systems to expand adoption of autonomous coding. source
• No decision has been made regarding the ultimate structure or timing of any potential transaction and any transaction would be subject to customary approvals including Board approval and regulatory requirements. source
• The company will evaluate a range of separation pathways with the objective of maximizing shareholder value. source

Impact estimates